Browse

Ed Silverman's Pharmalittle column notes that US biotech firms are wrestling with how to treat Chinese partners, with some seeing them as collaborators and others as competitors. The column highli…

For many years pharma companies treated legacy brands as low-maintenance cash generators, focusing only on steady but declining revenue once patents expired. With the largest patent cliff in histo…